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Summary.-Carrageenan (Cg) was tested for its effects on the growth of, and immu-
nity to, 2 methylcholanthrene-induced syngeneic murine fibrosarcomas (HI and H2).
The tumours werefound not to share majortumour-specifictransplantationantigens.
H2 appeared more immunogenic than HI. In contrast to HI, immunity induced by
H2 was not affected by Cg, nor was its growth in Cg-treated normal mice augmented.
Postoperative i.p. injections of Cg abolished the weak anti-HI immunity produced
by Hi tumour excision. Furthermore, the subsequent growth of the HI tumour
challenge in the Cg-treated immune mice was significantly greater than the aug-
mented growth in Cg-treated normal mice. The prior administration of the macro-
phage-stabilizing agent polyvinylpyrrolidone (PVP) to immune mice significantly
reduced the augmenting effect of Cg. The growth-promoting effect of Cg on a second-
ary HI tumour challenge in mice immunized by tumour excision was abolished by
106 MCT-Hi cells injected s.c. before Cg. In contrast to the immunity induced by
tumour excision, Cg did not abolish the immunity induced by the injection ofMCT-Hi
cells.
Passive administration of Hi tumour-bearer serum (TBS) did not enhance the
growth of Hi cells in normal mice, nor did TBS abrogate the specific cell-mediated
immunity (CMI) induced in vivo by MCT-Hl cells. However, TBS administered to
Cg-treated, MCT-Hl-immune mice abolished tumour immunity.
We propose that TBS does not inhibit CMI in vivo provided that macrophages re-
main functional, but may do so when macrophages are rendered defective by anti-
macrophage agents or by products of neoplastic cells. Increasing the levels of specific
effector cells can over-ride the inhibiting effects of TBS, even when defective macro-
phages are present.
TUMOUR-REJECTION IMMUNITY is a com-
plex process in which many components
of the lymphoreticular system interact,
but the principal effector cells appear to
be T lymphocytes and macrophages
(Alexander et al., 1972; Evans & Alex-
ander, 1971; Fink, 1976). T lymphocytes
separated from tumours have been shown
to have specific anti-tumour activity
(Gillespie et al., 1977; Plata & Sordat,
1977), and macrophages recovered from
tumours appear to be either cytostatic
(Evans, 1973; Haskill et al., 1975; Von
Loveran & den Otter, 1974) or cytocidal
(Russell et al., 1976).
Evidence in support of a role for
macrophage-like cells in amplifying
lymphocyte killing has been obtained
from studies both in vitro (Kearney et al.,
1975) and in vivo (Simes et al., 1975).
More direct evidence for the participation
of macrophages in tumour rejection has
been obtained by attempts to ablate
macrophages in vivo by a variety ofagents
including carrageenan, silica or trypan
blue (Zarling & Trevethia, 1973; Keller,
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1976; Kripke et al., 1977; Thomson &
Fowler, 1977; Nelson & Nelson, 1978).
Treatment by these agents, known to
diminish the functional capacity ofmacro-
phages in vitro, led to markedly aug-
mented growth ofmanytumours in normal
animals.
The aim of the present investigation
was to establish whether 2 chemically-
induced syngeneic tumours produce
specific immunity after either the ad-
ministration of mitomycin-C-treated
tumour cells (Benjamini et al., 1977) or the
surgical removal of tumour isografts, and
to determine whether the administration
of carrageenan altered the immunity in-
duced by either of the above methods.
MATERIALS AND METHODS
Animals.-Male mice (8-12 weeks old) of
the highly inbred CBA/H/WEH1 strain were
used. Their origin and maintenance have
been discussed previously (Basten et al.,
1974).
Tumours.-Two syngeneic methylcholan-
threne-induced fibrosarcomas designated HI
and H2 were used. Tumour-cell suspensions
were prepared from freshly excised tumours
by gently disaggregating tumour fragments
in 5-10 ml of 0.1% pronase in Dulbecco-
modified Eagles' medium (DME) as described
previously (Kearney & Nelson, 1973). The
cell suspension obtained was washed x3 in
DME containing 15% foetal calf serum
(FCS). Cells were finally suspended in serum-
free medium and the the viability deter-
mined by trypan-blue exclusion. Viable
tumour-cell suspensions inserum-free medium
were adjusted to the appropriate concentra-
tion indicated for particular experiments.
Viable tumour cells were injected s.c. in a
volume of 0-2 ml along the midline of the
abdominal wall. At daily intervals, usually
after the 4th day, the smallest and largest
diameters of the tumours were measured (to
the nearest 0-1 mm) by a Schnelltaster dial
gauge (Kearney & Nelson, 1973) or by
vernier calipers. The tumour diameter was
expressed as the average of both diameters,
and corrected for average thickness of the
uninjected mouse skin-fold of the abdominal
wall. The mean tumour diameters are re-
recorded with their standard errors.
Excision and rechallenge assays of tumour
immunity.-Mice were immunized with living
tumour inoculated s.c. in the flank, followed
by tumour excision. The faster-growing HI
tumour was inoculated in a dose of 106 cells,
which developed 10-15mm sarcomas within
10-12 days, when they were excised under
ether anaesthesia. The slower-growing H2
tumour, in a dose of 107 cells, grew to about
the same size within 12-14 days, when they
were similarly excised. Six weeks after sur-
gical excision, these mice and control mice
were challenged s.c. along the midline of the
abdominalwallwiththeappropriate challenge
dose as indicated in the particular experi-
ments.
Preparation of mitomycin-C-treated tumour
cells (MCT cells).-Tumour cells obtained by
incubation with 0-1% pronase in DME
medium were washed x3 in DME medium
with 20% FCS. Mitomycin C (MC) (Kyowa
Hakko Kygyo Co. Ltd, Japan) was dis-
solved in DME with 20% FCS and then
added to the tumour cells at a concentration
of30 ,ug/106 HI tumour cells/ml medium. The
cells were incubated at 37°C for 35 min, and
then washed x3 in medium alone to remove
free MC and FCS. Viability oftotal nucleated
cells treated in this way usually exceeded
95%. Recurrence of tumour growth of MCT
cells was not observed in the present experi-
ments. A single dose of 106 MCT cells was
injected s.c. in the flank to induce specific
immunity (Wu & Kearney, submitted for
publication) and these mice were challenged
14 days later.
Carrageenan (Cg). Lambda carrageenan
(Marine Colloids Inc., Springfield, New
Jersey) was dissolved in boiling saline at a
concentration of 0 5 mg/0.2 ml, and then
stored at -20°C until required. The amount
of Cg administered varied according to the
particular experiment but in general, animals
were given 0 5 mg of Cg injected i.p. on each
of 3 days before the test procedure, i.e.,
before inoculation of MCT tumour cells, or
before subsequent challenge-inoculation with
viable tumour cells. On the day ofthe experi-
ment, a final dose of0 5 mg was administered
about 1 h before the antigen. Thus, a total
dose of 2 mg was administered in 4 fractions.
Polyvinylpyrrolidone (PVP).-PVP (May
and Baker Ltd, Dagenham, England; Lot
49614), mol. wt 30,000-40,000, was dissolved
in saline at a concentration of 8 mg/ml. One
day before the first dose of Cg, mice were
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injected i.p. with 0 5 ml PVP. On the follow-
ing day, 1 h before mice received Cg, 0-25 ml
PVP was injected both i.p. and s.c. Thus a
total of 20 mg PVP was injected into each
mouse over a 5-day period before tumour
challenge.
RESULTS
Preliminary experiments established
that the threshold doses of 0.5 x105 for
the HI tumour and 5 X 105 for the H2
tumour would develop into palpable
tumours in all mice within 2 weeks, and
were therefore used as the standard
challenge inocula to detect weak immunity
in the in vivo assays.
Magnitude of the immune response to the
HI tumour after tumour excision
The strength of the resistance acquired
by HI tumour excision was assessed by
injecting mice (in groups of 8-12) with
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0 5 x 105, 1 X 105 and 5 X 105 viable HI
cells.
Fig. 1 shows that tumour resistance 6
weeks after excision is weak, since a dose
of only 0-5x 105 cells, but not of 5x105
cells, was completely rejected. The growth
rate in the latter mice was less initially
than that of the control mice, suggesting
that the growth of some tumour cells was
arrested. Mice challenged with an inter-
mediate dose of 105 cells showed variable
resistance.
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FIG. 1.-Effect of dose of HI tumour chal-
lenge inoculated s.c. into the abdominal
wall of normal CBA mice, and mice immu-
nized by removal of syngeneic Hi tumour
isograft 6 weeks before. Normal mice
challenged with: 0 5 x 105, * 0;
1 X 105, 0 O; 5x 105, A A. Im-
mune mice challenged with: 0 5 x 105 cells,
A - - - 0; 1 x 105 cells, (0); 5x 105 cells,
A --- A. Each point on the lines repre-
sents the mean values for 8-12 mice per
group.
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FIG. 2.-The effect ofcarrageenan (Cg) on the
growth of 0-5 x 105 syngeneic HI tumour
cells inoculated s.c. into the abdominal
wall of normal CBA mice, and mice immu-
nized by excision of HI tumour isografts
6 weeks before.
Growth of HI cells in: 8 normal mice,
* *; 8 Cg-treated normal mice,
O O; 11 immune mice, * *;
10 Cg-treated immune mice, 0 --- 0.
~~~~~~.
. * . . . . .
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Effect of carraayeenan on the tumnour resist-
ance of mice immnunized by the excision of
HI tumour isografts
To assess the effect, of Cg on tumouir
resistance acquired by tumour excision,
immune mice (12 -14 per group) were in-
jected i.p. with a total of 2 mg Cg given in
4 daily 0 5 mg doses during the 6th week
after H1 tumour excision. The last dose of
(g was given 1 h before a tumour chal-
lenge of 05x 105 HI cells s.c.
Fig. 2 shows that Cg abolished the
immunity to the HI tumour inoculum,
and that the subsequent tumour growth
was significantly greater (from Day 9) than
the augmented growth in Cg-treated
normal mice.
Effect of carrayeenan on the yrowth of HI
and H2 tumours in mice immunized by
MCT-H2 inoculation
Eight mice in each of 4 groups were
injected s.c. in the flank with 106 MCT-H2
cells. Mice in 2 of the MCT-H2 treated
groups were injected i.p. with 2 mg Cg in
4 daily 05mg doses before tumour chal-
lenge 14 days after MCT inoculation. Con-
trol mice with or without Cg were in-
cluded. Mice were challenged with either
05x 105 HI or 5x105 12 tumour cells
injected s.c.
Fig. 3 shows that the immunity in-
duced by MCT-H2 injection led to the
rejection of 5x105 H2 tumour cells but
not of 0*5X105 HI tumour cells. Cg did
not affect the expression of MCT-H2 re-
sistance to the H2 tumour, nor did Cg
augment the growth of H2 tumours in
normal mice. Cg did, however, augment the
growth of HI tumour cells inoculated into
MCT-H2-immune mice. No evidence was
found, therefore, that HI and H2 tumours
shared major tumour-specific transplanta-
tion antigens.
Effect of carrageenan on the growth on HI
and H2 tumours in mice immunized by
excision of H2 tumour isografts
Concurrent with the previous experi-
ments, 8 mice, in each of 4 groups,
immunized by excision of H2 tumour
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Fi(e. 3. Effect, of carrageenan (Cg) on the
growth of syngeneic HI and H2 tumouirs
injecte(l s.c. into the abdominal wall of
normal CBA mice, and mice immunized by
106 mitomycin-C-treated H2 tumour cells
(MCT-H2) 14 days before. Cg (2 mg) was
a(lministere(l i.p., after MCT-H2 treatment,
over a :3-dlay period before secondiar,y
tumouir challenge.
Growth of 05 x 105 HI cells in: inormal
mice, 0 *; Cg-treate(d normal mIic(e
MCT-H2-immune mice,
A A; Cg-treated MCT-H2-immune
mice, A A.
Growth of 5 x 105 H2 cells in: inormal
mice, *---- *; Cg-treat,ed normal
mice, H ---- n; MCT-H2-immune mice,
* *; Cg-treated MCT-H2-immtiiie
mice, n- °
Each point represents the mean of 8
mice.
isografts, were challenged 6 weeks later
with either 0 5x105 HI or 5x105 H2
tumour cells. Immune mice in 2 of the
groups were pretreated with Cg as already
described. Control mice of similar num-
bers were included.
Fig. 4 shows that excision of the H2
tumour isograft led to total resistance to
the H12 tumour, but was ineffective
against the HI tumour. In contrast to the
augmenting effect of Cg on HI tumour
growth in mice immunized by excision of
the HI tumour, Cg did not abolish the
specific resistance acquired by H2 tumour
excision, thus indicating other differences
6, I
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of 106 MCT-H1 cells, before the adminis-
tration of Cg to mice, prevented the aug-
mented tumour growth found when Cg
was administered to mice immunized by
tumour excision. Sixteen mice, in each of
four groups, were immunized by excising
HI isografts as described. Four weeks
later, immune mice in 2 ofthe groups were
injected s.c. in the flank with 106 MCT-HI
cells. During the 6th week, immune mice
in one of the MCT-treated groups were
injected i.p. with 2 mg Cg as before. Ofthe
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Fie. 4.-Effect of carrageenan (Cg) on the
growth of syngeneic HI and H2 tumours
injected s.c. into the abdominal wall of
normal CBA mice, and mice immunized by
excision of H2 tumour isografts 6 weeks
before. Cg (2 mg) was administered i.p.
over a 3-day period before secondary
challenge.
Growth of 0 5 x 105 HI cells in: normal
mice, * 0; Cg-treated normal mice,
O O; H2-immune mice, A A;
Cg-treated H2-immune mice, A- A.
Growth of 5 x 105 H2 cells in: normal
mice, O---- C-1; H2 immune mice,
* --- *; Cg-treated H2 immune mice.
O --- O.
Each point on the graph represents the
mean of 8 mice.
in the properties of the non-cross-reacting
HI and H2 tumours.
Abolition ofcarrageenan-induced augmenta-
tion ofgrowth ofHi tumour in mice immune
by pretreatment with MCT-H1 cells
Previous studies (Wu & Kearney, sub-
mitted for publication) had shown that
mice injected s.c. with a single dose of 106
MCT-H1 cells developed specific immunity
which, after 7 days, resisted a challenge
inoculum of 0-5 x 105 HI cells. Only par-
tial resistance, however, was obtained
against challenge doses greater than 0 5
x 105 HI cells in such mice.
The following experiments were de-
signed to test whether a single inoculation
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FIG. 5.-Effect of the administration of 106
mitomycin-C-treated HI tumour cells
(MCT-H1) on the enhancing effect of Cg on
HI tumour challange in CBA mice immu-
nized by the excision of syngeneic HI
tumour isografts 6 weeks before. Cg (2 mg)
was administered i.p. over a 3-day period
before secondary tumour challenge. MCT-
HI cells were injected s.c. 14 days before
secondary tumour challenge.
Growth of 0.5 x 105 HI cells in: normal
mice, * *; Cg-treated normal mice,
O O; tumour-excised immune mice,
* *; Cg-treated, tumour-excised im-
mune mice, O --- O; MCT-HI-injected
mice, A A; Cg-treated, MCT-H1 in-
jected mice, A A; Cg-treated, MCT-
HI injected, tumour-excised immune mice,
E]
Tumour-excised immune mice, pretreated
with MCT-HI cells, all resisted growth (not
shown) of the challenge inoculum. Each
point represents the mean of 8-12 mice.
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2 remaining groups of immune mice, one
was given Cg while the other was left un-
treated. Eight normal mice in each of the
control groups were similarly treated with
MCT-H1 cells or Cg, or both. In the 6th
week, all mice, including 8 untreated mice,
were challenged with 0.5 x 105 HI cells
injected s.c. soon after the last dose ofCg.
Fig. 5 shows that although Cg abolished
the resistance acquired by tumour ex-
cision, it did not inhibit the immunity
induced by a single injection of 106 MCT-
HI cells. Furthermore, results show that
the augmenting effect of Cg in mice
immunized by tumour excision can be
prevented by a single s.c. injection of 106
MCT-H1 cells 14 days before tumour
challenge. Mice immunized by tumour
excision and treated with MCT-H1 cells
retain their immunity (results not shown).
Effect ofpolyvinylpyrrolidone (PVP) on the
tumour-augmenting property of Cg in
normal and immune mice
Mice, in groups of 6-8, immunized by
HI tumour excision, were treated with
either PVP, Cg or both before secondary
HI challenge 8 weeks after tumour ex-
cision. Table I shows the mean diameters
of the tumours in mice of both test and
control groups 19 days after challenge
with 0 5 x 105 HI cells. PVP signifi-
cantly reduced the tumour-promoting
effect of Cg in the groups of immune and
normal mice. Fig. 6 illustrates the relative
sizes of representative tumours from each
ofthe groups.
Effect of serumfrom animals with progress-
ing tumours on immunity of animals
immunized with MOT cells
Although MCT-Hl cells induce an
effective, cell-mediated anti-tumour re-
sistance, this response could not be de-
tected when MCT cells were injected into
animals with established tumours (Wu &
Kearney, submitted for publication). One
possibility is that animals with growing
tumours have serum factors which can
prevent the expression of cell-mediated
cytotoxic effects on tumour cells. This
effect has been detected by in vitro assays
(Hellstrom & Hellstrom, 1974) but their
relevance in vivo has been questioned.
The following experiments are based on
the observation that the response to MCT
cells appears to be only cell-mediated
(Benjamini et al., 1977; Wu & Kearney,
submitted for publication) and that there-
fore any serum factor present in tumour-
bearing mice which interferes with cell-
mediated mechanisms should be easily
detected. Tumour-bearer serum (TBS)
was obtained by bleeding mice 4, 5, 6 and
7 days after s.c. inoculation of 2 x 106 live
Hi cells in the flank. Serum samples were
pooled from 20-30 donor animals and
stored at -20°C. Normal mouse serum
TABLE I.-Inhibition by polyvinylpyrrolidone (PVP) of the growth-augmenting effect of
carrageenan (Cg) on the Hi tumour in normal and immune mice
Diam. of
tumour
HI tumour PVP challenge in
isograft treatment; Cg treatment; site at
and 4 mg daily, 0 5 mg daily, Day 19
excision 5 days before 4 days before Mean±s.e.
Code (Exc) challenge challenge (Units 0-1 mm)
N/Hi - 125± 7
N/PVP/H1 - + _ 98±8
N/Cg/Hl - -1+ 156±10
N/PVP/Cg/Hl - + + 135{9
Exc/Hl + 0
Exc/PVP/H1 + + 0
Exc/Cg/Hl + - + 181±15
Exc/PVP/Cg/Hl + + + 70±4
Mice challenged s.c. with 0 5 x 105 Hi tumour cells 8 weeks after tumour excision.
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FIG. 6.-Effect ofPVP growth ofHI1 tumours in normal and immune mice treated or not with Cg after
tumour excision. Photo illustrates the size of 2 representative tumours in each group shown in
Table I 19 days after secondary challenge inoculation with 0 5 x 105 Hi cells. Explanation of code
in Table I.
(NMS) was pooled from 20-30 donor mice.
In this experiment MCT-H1-immunized
mice were injected i.p. with 0 9 ml of
TBS or 0*9 ml of NMS on the 14th day
after immunization. Unimmunized age-
matched controls received the same treat-
ment. One hour after receiving serum, all
animals were injected s.c. with 05x 105
HI cells along the midline of the ab-
dominal wall. Results are shown in Table
II and Fig. 7, where it is seen that TBS
appeared to have no effect on the growth
of the tumour in normal mice, and no
effect on the ability ofimmunized mice to
express resistance.
Effect of tumour-bearer serum on immunity
in carrageenan-treated animals immunized
with MCT-H1 cells
Mice were immunized with MCT-H1
cells as in the previous experiment. Be-
ginning 10 days after immunization, half
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TABLE II.-Effect of normal and tumour-
bearer serum on immunity induced by
injection of mitomycin-C-treated HI
tumour cells in mice
Immuniza- Serum
tion 0-9 ml i.p.
- NMS
- TBS
+
+ NMS
-4 TBS
Tumour
incidence
at Day 17
8/8
7/7
8/8
0/5
3/6
0/7
NMS, normal mouse serum; TBS, tumour-bearer
serum. 106 MCT-HI cells injected s.c. into the flank
to immunize. Donor TBS was obtained by bleeding
mice 4, 5, 6, and 7 days after inoculation of 2 x 106
live HI cells. Recipient mice were injected i.p. 14
days after sensitization with MCT-HI cells, and 1 h
before challenge with 0-5 x 105 HI cells.
10
__ g
8
+,
= 7
5~ 6
af 5 o5
CD
2
4 5 6 7 8 9 10 11 12 13 14 15
DAYS AFTER CHALLENGE
FIG. 7.-Effect on H I tumour growth of
0-9 ml tumour-bearer serum injected i.p.
* *, 0-5x 105 HI tumour alone, s.c.;
A ---- , 0 5 x 105 H1 tumour cells+
normal mouse serum; 0 --- 0, 0-5 x 105
HI tumour cells+tumour-bearer serum.
the mice and the same number of age-
matched unimmunized controls began Cg
treatment. On the 14th day after im-
munization, animals received 1-0 ml of
TBS (collected 5, 6, 7 and 8 days after a
challenge of 3 x 106 HI cells) or NMS by
i.p. injection. One hour later the animals
were challenged with 0 5 x 105 HI cells
s.c. as before. Results recorded in Table III
confirm the previous observation, and
show that the immunity of mice given
MCT-H1 cells could be abrogated by pre-
TABLE III.-Effect of nornal and tumour-
bearer serum in normal and immune mice
treated with or without carrageenan (Cg)
Immuniza-
tion1
Serum Tumour
1-0 ml incidence
Cg i.p. at Day 18
- 8/8
+ 8/8
- NMS1 7/7
+ NMS 7/7
- TBS1 8/8
+ TBS 8/8 _ 1/7
+ 0/7
- NMS 2/7
+ NMS 1/6
- TBS 1/6
+ TBS 6/7
1 As in Table II (q.v.). Lambda carrageenan;
2 mg injected i.p. between Days 10 and 14 after
MCT-H1 inoculation. TBS collected from donormice
5, 6, 7, and 8 days after inoculation with 3 x 106 HI
cells. Recipient mice were injected i.p. 14 days after
MCT-HI inoculation, and 1 h before challenge with
0-5 x 105 Hi tumour cells.
treatment with Cg together with adminis-
tration of TBS, although either of these
treatments alone had no effect (Table III).
In Tables II and III, the tumours which
occurred in immune mice treated with
NMS were significantly smaller than those
in normal mice treated with NMS.
DISCUSSION
Cg has many biological effects (Di Rosa,
1972) including inhibition ofblood coagu-
lation (Anderson & Duncan, 1965) and the
complement system (Davies, 1965). Cg
also has the ability to interfere with anti-
body reactions in vivo (Ishizaka et al.,
1977). In addition, the substance is toxic
for macrophages in vttro (Catanzaro et al.,
1971) and in vivo (Nelson & Nelson, 1978).
Its augmenting effect upon syngeneic
tumours has been reported by several
workers (Keller, 1976; Thomson & Fowler,
1977; Nelson & Nelson, 1978). Keller
(1976) suggested that the augmented
tumour growth could be explained by a
diminished period of macrophage function
leading to successful tumour implantation
and initiation of progressive growth. In
support of this interpretation, Keller
(1976) found that the augmenting effects
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of C(g (and silica) on tumour growth were
reversed by the macrophage-stabilizing
agent poly - 2 - vinylpyridine N - oxide
(PVNO) a substance known to reverse
the immunosuppressive effect of silica and
Cg (Rios & Simmons, 1972). However,
Keller (1976) observed that tumourgrowth
could also be increased by a growth-
promoting agent released from damaged
macrophages.
In the present experiments, Cg greatly
increased the growth of the low-immuno-
genic HI tumour in mice immunized by
tumour excision and then treated with Cg
before secondary challenge. In direct con-
trast, however, Cg had no effect on the
same tumour when inoculated into mice
immunized by MCT-H1 cells. This differ-
ence must be due to the differences in the
type of immunity induced by tumour
excision and MCT inoculation. Evidence
by Benjamini et al. (1977) and Wu &
Kearney (submitted for publication) re-
vealed that the development of MCT-
induced immunity was paralleled by the
development ofspecific cell-mediated cyto-
toxicity without the formation of detect-
able anti-tumour antibodies. On the other
hand, specific immunity acquired by
tumour excision is mediated by both cyto-
toxic cells (Belehradek et al., 1972) and
antibody (Pilch & Riggins, 1966). By
using a modification of the method de-
scribed by Brown et al. (1977), sera from
Hf1 tumour-bearing mice and from mice
immunized by tumour excision were found
to possess specific antibody to the HI
tumour (Kearney, to be published). How-
ever, similar antibody activity could not
be found in sera of mice immunized by
MCT-H1 cells. Therefore, in addition to
the magnitude of the immune responses, a
major factor which could also determine
whether tumour growth is enhanced or not
in immune mice pretreated with Cg is
whether antibody accompanies the cell-
mediated response.
The in vitro cell-mediated response to
the HI tumour is feeble, and depends upon
the amplification of the weak cytotoxic
Fffect of the T-cell component by macro-
phage-like cells (Kearney et al., 1975;
Nelson et al., 1978). The present experi-
ments show that the immunity acquired
in vivo by either surgical removal of the
H1 tumour or MCT treatment is also weak.
The effect of Cg on macrophages could
account for the even lower resistance
found in mice whose primary isograft had
been removed. The macrophage-stabilizing
properties of PVP (Hochschild, 1973)
largely reversed the augmenting effect of
Cg in mice immunized by HI-tumour ex-
cision. The situation is clearly different in
MCT-immunized mice, in which the im-
munity is not abrogated by Cg. Possibly
the numbers of specific effector T cells in
Cg-treated MCT-immune mice were able
to control the growth of a challenge
tumour inoculum in the absence ofantibody
without the presence of functional macro-
phages.
The loss of immunity in Cg-treated
mice immunized by tumour excision may
have been due to the inhibition of cyto-
toxic effector cells by a serum factor, pre-
sumably antibody, in the absence of
functional macrophages.
Cg does not abolish pre-existing hum-
oral immunity to sheep erythrocytes,
but the secondary response to sheep
erythrocytes in Cg-treated mice is delayed
(Kearney & Orr, unpublished). A similar
delay in the secondary antibody response
to the HI tumour challenge could account
for the delay in the enhancement pheno-
menon in Cg-treated mice immunized by
tumour excision (see Figs. 2 & 5). The
abolition of Cg-induced augmentation by
prior inoculation of MCT cells in mice
immunized by tumour excision may be
attributed to an increase in the level of
effector cells akin to a booster-like effect
seen when irradiated cells are adminis-
tered after surgical excision (Le Francois
et al., 1971; Belehradek et al., 1972). Such
an increase in the level of specific cyto-
toxic cells may override the inhibiting
effect of antibody, and also compensates
for a loss of accessory macrophages
rendered non-functional by Cg. This view
is consistent with the observation of
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Simes et al. (I975), in which small numbers
of lymphocytes were ineffective in killing
similar tumour cells in vivo without
accessory radio-sensitive marrow-derived
cells (presumably macrophages), whilst
larger numbers were effective alone.
Taken together, these findings may
help to explain the failure of Cg to aug-
ment the growth of the H2 tumour in
normal mice, and the failure of Cg to
abolish resistance in immune mice. Such
an escape from the effects of Cg may de-
pend upon the H2 tumour being more
immunogenic and thus inducing greater
immune response which is not completely
dependent upon the presence of macro-
phages for its expression.
In view of previous observations and
those reported in the present study, we
wish to set forth an hypothesis to explain
certain features of tumour growth in Cg-
treated normal and immune mice.
We propose that tumour-bearer serum
does not abrogate cell-mediated im-
munity to tumours in vivo when macro-
phages are functional. Cg, a known in-
hibitor of macrophage function, will aug-
ment the growth of weakly immunogenic
tumours. In situations where the cell-
mediated immunity is weak, the presence
of defective macrophages does not negate
the cytotoxic T-cell function, provided
antibody is absent, as in MCT-induced
immunity. However, specificantibody and
defective macrophages, if present when
specific cell-mediated cytotoxicity is weak,
will abolish cellular resistance, as seen
mice with feeble immunity induced
tumour-excision and subsequently treat-e
with Cg. In contrast, the blocking effect of
immune serum, in the presence ofdefective
macrophages, is abolished when the popu-
lation ofspecific effector cells is increased,
as seen when mice, immunized by tumour
excision, are boosted by MCT cells before
Cg treatment. This explains why tumours
which induce strong cell-mediated im-
munity are less likely to be affected by
anti-macrophage agents. Weak immuno-
genicity would seem to confer a significant
biological advantage to tumour cells.
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